candesartan has been researched along with Amentia in 3 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether candesartan-based antihypertensive treatment in elderly patients with mildly to moderately elevated blood pressure confers a reduction in cardiovascular events, cognitive decline and dementia." | 5.10 | The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. ( Elmfeldt, D; Hansson, L; Hofman, A; Lithell, H; Olofsson, B; Skoog, I; Trenkwalder, P; Zanchetti, A, 2003) |
| "Arterial hypertension is closely correlated with the occurrence of stroke and also with the loss of cognitive function and dementia." | 2.42 | Neurological protection provided by candesartan: reviewing the latest study results. ( Leys, D, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lithell, H | 1 |
| Hansson, L | 1 |
| Skoog, I | 1 |
| Elmfeldt, D | 1 |
| Hofman, A | 1 |
| Olofsson, B | 1 |
| Trenkwalder, P | 1 |
| Zanchetti, A | 1 |
| Leys, D | 1 |
| Williams, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2007-09-30 | Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for candesartan and Amentia
| Article | Year |
|---|---|
Neurological protection provided by candesartan: reviewing the latest study results.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2003 |
Protection against stroke and dementia: an update on the latest clinical trial evidence.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2004 |
1 trial available for candesartan and Amentia
| Article | Year |
|---|---|
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Bl | 2003 |